Intestinal microbiota and short-chain fatty acids in patients with post-COVID immune response
Open Access
- 20 December 2025
- journal article
- Published by Publishing House Zaslavsky in GASTROENTEROLOGY
- Vol. 59 (4) , 249-254
Abstract
Background. The intestinal microbiota and its metabolites play a pivotal role in the progression of liver diseases. The COVID-19 pandemic has led to a growing number of patients with metabolic-associated steatotic liver disease (MASLD), the course of which is often complicated by microbiota imbalance, acting as a key factor in hepatic metabolic and inflammatory alterations. The purpose was to assess the quantitative and qualitative composition of colonic microbiota and its metabolites in patients with metabolic-associated steatotic liver disease and immune response to SARS-CoV-2. Materials and methods. A total of 112 patients, 75 men (66.9 %) and 37 women (33.1 %), with MASLD aged 18–73 years (mean age (46.4 ± 1.5) years) were examined. The serum level of SARS-CoV-2-specific IgG antibodies was determined using the enzyme-linked immunosorbent assay. The concentration of short-chain fatty acids in feces was measured by gas chromatography. The quantitative and species composition of colonic microbiota was studied by tenfold serial dilution (10–1–10–9) using standard elective and differential diagnostic media for the isolation of aerobic and anaerobic microorganisms. Results. Patients with MASLD and immune response to SARS-CoV-2 demonstrated pronounced alterations in the intestinal microbiota profile. Grade II dysbiosis predominated in patients who had COVID-19 and grade I dysbiosis predominated in those without a history of infection. In post-COVID-19 patients, deeper disturbances were revealed, including a decrease in Bifidobacterium (28.3 %) and Lactobacillus (70.0 %) concentrations and a higher detection rate of conditionally pathogenic Enterobacteriaceae. Conclusions. Patients with MASLD and immune response to SARS-CoV-2 exhibit significant intestinal microbiota dysbiosis and imbalance of short-chain fatty acids. These findings emphasize the importance of early diagnosis and targeted correction of gut microbiota as an integral component of therapeutic strategies in this patient population.Keywords
This publication has 24 references indexed in Scilit:
- Gut Microbiota and COVID-19: Unraveling the Gut–Lung Axis and Immunomodulatory TherapiesACS Infectious Diseases, 2025
- The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosisNaunyn-Schmiedeberg's Archives of Pharmacology, 2025
- Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyondHepatology Communications, 2023
- Gut microbiota in COVID-19: new insights from insideGut Microbes, 2023
- Short-chain fatty acids–microbiota crosstalk in the coronavirus disease (COVID-19)Pharmacological Reports, 2022
- Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamstersGut Microbes, 2021
- Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19Gastroenterology, 2021
- Gut microbiota and renin-angiotensin system: a complex interplay at local and systemic levelsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2021
- Neuropsychiatric Ramifications of COVID‐19: Short‐Chain Fatty Acid Deficiency and Disturbance of Microbiota‐Gut‐Brain Axis SignalingBioMed Research International, 2021
- Gut microbiota in non‐alcoholic fatty liver disease and alcohol‐related liver disease: Current concepts and perspectivesHepatology Research, 2019